Statement Regarding FDA's NDIN Rejection Letters


FOR IMMEDIATE RELEASE
August 12, 2021

CONTACT
Katelyn Wiard
U.S. Hemp Roundtable
info@hempsupporter.com


U.S. HEMP ROUNDTABLE STATEMENT REGARDING
FDA NDIN REJECTION LETTERS


(WASHINGTON) - The U.S. Hemp Roundtable is deeply disappointed to witness FDA’s rejection of two dietary ingredient notifications (NDINs) recently submitted for full spectrum hemp extracts. FDA’s actions send a discouraging message to the entire hemp and CBD industry, especially in light of the fact that these firms provided more than ample safety data and cooperated with FDA’s requests throughout the process. When held to the same regulatory standards as other dietary supplements and food ingredients, hemp-derived CBD products have a strong safety profile; the dangers to consumers are only posed by the unregulated marketplace that FDA continues to propagate.

This should be a clarion call to Congress that it is time to step in and pass legislation to ensure that CBD products are held to the same standard as all dietary supplements and food ingredients, and to reject an NDIN-only path. It’s been more than two and a half years since hemp was legalized by the 2018 Farm Bill, and without congressional intervention, the hemp farming industry will continue to struggle, and consumers stand to lose as well.


ABOUT
The U.S. Hemp Roundtable is the hemp industry’s national advocacy organization, a coalition of dozens of leading companies and organizations committed to safe hemp and CBD products. The Roundtable proudly works in partnership with the industry's leading national, regional and state grassroots organizations, and is leading the way forward for hemp and CBD products through education and action. More at hempsupporter.com.


State action icon

Take Action In Your State

Make Your Voice Heard

Track the latest hemp and CBD legislative developments in all 50 states and contact your elected representatives to demand action.

Go to the State Action Center